Dr. Ledermann on Rucaparib Maintenance in Ovarian Cancer

Jonathan Ledermann, MD
Published: Wednesday, Nov 15, 2017



Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses rucaparib (Rubraca) maintenance in ovarian cancer.

The ARIEL3 trial is currently looking at maintenance therapy with rucaparib by giving patients chemotherapy, and then maintaining the response and freedom from progression by using a PARP inhibitor. Rucaparib is licensed in the United States for the treatment of BRCA-mutated ovarian cancer.

ARIEL3 is the third randomized trial in this setting.
 


Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses rucaparib (Rubraca) maintenance in ovarian cancer.

The ARIEL3 trial is currently looking at maintenance therapy with rucaparib by giving patients chemotherapy, and then maintaining the response and freedom from progression by using a PARP inhibitor. Rucaparib is licensed in the United States for the treatment of BRCA-mutated ovarian cancer.

ARIEL3 is the third randomized trial in this setting.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Redefining Ovarian Cancer Treatment Paradigms by Maximizing Therapeutic Outcomes with PARP InhibitorsSep 29, 20182.0
Community Practice Connections™: 1st Annual School of Nursing Oncology™Oct 31, 20181.5
Publication Bottom Border
Border Publication
x